Temporal and geographical external validation study and extension of the Mayo Clinic prediction model to predict eGFR in the younger population of Swiss ADPKD patients

Laura Girardat-Rotar, Julia Braun, Milo A. Puhan, Alison Gump Abraham, Andreas L. Serra

Research output: Contribution to journalArticle

Abstract

Background: Prediction models in autosomal dominant polycystic kidney disease (ADPKD) are useful in clinical settings to identify patients with greater risk of a rapid disease progression in whom a treatment may have more benefits than harms. Mayo Clinic investigators developed a risk prediction tool for ADPKD patients using a single kidney value. Our aim was to perform an independent geographical and temporal external validation as well as evaluate the potential for improving the predictive performance by including additional information on total kidney volume. Methods: We used data from the on-going Swiss ADPKD study from 2006 to 2016. The main analysis included a sample size of 214 patients with Typical ADPKD (Class 1). We evaluated the Mayo Clinic model performance calibration and discrimination in our external sample and assessed whether predictive performance could be improved through the addition of subsequent kidney volume measurements beyond the baseline assessment. Results: The calibration of both versions of the Mayo Clinic prediction model using continuous Height adjusted total kidney volume (HtTKV) and using risk subclasses was good, with R2 of 78% and 70%, respectively. Accuracy was also good with 91.5% and 88.7% of the predicted within 30% of the observed, respectively. Additional information regarding kidney volume did not substantially improve the model performance. Conclusion: The Mayo Clinic prediction models are generalizable to other clinical settings and provide an accurate tool based on available predictors to identify patients at high risk for rapid disease progression.

Original languageEnglish (US)
Article number241
JournalBMC Nephrology
Volume18
Issue number1
DOIs
StatePublished - Jul 17 2017

Fingerprint

Autosomal Dominant Polycystic Kidney
Validation Studies
Kidney
Population
Calibration
Disease Progression
Sample Size
Research Personnel

Keywords

  • ADPKD
  • Disease progression
  • Epidemiology
  • Kidney volume
  • Prediction model
  • Validation study

ASJC Scopus subject areas

  • Nephrology

Cite this

Temporal and geographical external validation study and extension of the Mayo Clinic prediction model to predict eGFR in the younger population of Swiss ADPKD patients. / Girardat-Rotar, Laura; Braun, Julia; Puhan, Milo A.; Abraham, Alison Gump; Serra, Andreas L.

In: BMC Nephrology, Vol. 18, No. 1, 241, 17.07.2017.

Research output: Contribution to journalArticle

@article{c0cb5da8bc3f406d8dd89974e1e485b5,
title = "Temporal and geographical external validation study and extension of the Mayo Clinic prediction model to predict eGFR in the younger population of Swiss ADPKD patients",
abstract = "Background: Prediction models in autosomal dominant polycystic kidney disease (ADPKD) are useful in clinical settings to identify patients with greater risk of a rapid disease progression in whom a treatment may have more benefits than harms. Mayo Clinic investigators developed a risk prediction tool for ADPKD patients using a single kidney value. Our aim was to perform an independent geographical and temporal external validation as well as evaluate the potential for improving the predictive performance by including additional information on total kidney volume. Methods: We used data from the on-going Swiss ADPKD study from 2006 to 2016. The main analysis included a sample size of 214 patients with Typical ADPKD (Class 1). We evaluated the Mayo Clinic model performance calibration and discrimination in our external sample and assessed whether predictive performance could be improved through the addition of subsequent kidney volume measurements beyond the baseline assessment. Results: The calibration of both versions of the Mayo Clinic prediction model using continuous Height adjusted total kidney volume (HtTKV) and using risk subclasses was good, with R2 of 78{\%} and 70{\%}, respectively. Accuracy was also good with 91.5{\%} and 88.7{\%} of the predicted within 30{\%} of the observed, respectively. Additional information regarding kidney volume did not substantially improve the model performance. Conclusion: The Mayo Clinic prediction models are generalizable to other clinical settings and provide an accurate tool based on available predictors to identify patients at high risk for rapid disease progression.",
keywords = "ADPKD, Disease progression, Epidemiology, Kidney volume, Prediction model, Validation study",
author = "Laura Girardat-Rotar and Julia Braun and Puhan, {Milo A.} and Abraham, {Alison Gump} and Serra, {Andreas L.}",
year = "2017",
month = "7",
day = "17",
doi = "10.1186/s12882-017-0654-y",
language = "English (US)",
volume = "18",
journal = "BMC Nephrology",
issn = "1471-2369",
publisher = "BioMed Central",
number = "1",

}

TY - JOUR

T1 - Temporal and geographical external validation study and extension of the Mayo Clinic prediction model to predict eGFR in the younger population of Swiss ADPKD patients

AU - Girardat-Rotar, Laura

AU - Braun, Julia

AU - Puhan, Milo A.

AU - Abraham, Alison Gump

AU - Serra, Andreas L.

PY - 2017/7/17

Y1 - 2017/7/17

N2 - Background: Prediction models in autosomal dominant polycystic kidney disease (ADPKD) are useful in clinical settings to identify patients with greater risk of a rapid disease progression in whom a treatment may have more benefits than harms. Mayo Clinic investigators developed a risk prediction tool for ADPKD patients using a single kidney value. Our aim was to perform an independent geographical and temporal external validation as well as evaluate the potential for improving the predictive performance by including additional information on total kidney volume. Methods: We used data from the on-going Swiss ADPKD study from 2006 to 2016. The main analysis included a sample size of 214 patients with Typical ADPKD (Class 1). We evaluated the Mayo Clinic model performance calibration and discrimination in our external sample and assessed whether predictive performance could be improved through the addition of subsequent kidney volume measurements beyond the baseline assessment. Results: The calibration of both versions of the Mayo Clinic prediction model using continuous Height adjusted total kidney volume (HtTKV) and using risk subclasses was good, with R2 of 78% and 70%, respectively. Accuracy was also good with 91.5% and 88.7% of the predicted within 30% of the observed, respectively. Additional information regarding kidney volume did not substantially improve the model performance. Conclusion: The Mayo Clinic prediction models are generalizable to other clinical settings and provide an accurate tool based on available predictors to identify patients at high risk for rapid disease progression.

AB - Background: Prediction models in autosomal dominant polycystic kidney disease (ADPKD) are useful in clinical settings to identify patients with greater risk of a rapid disease progression in whom a treatment may have more benefits than harms. Mayo Clinic investigators developed a risk prediction tool for ADPKD patients using a single kidney value. Our aim was to perform an independent geographical and temporal external validation as well as evaluate the potential for improving the predictive performance by including additional information on total kidney volume. Methods: We used data from the on-going Swiss ADPKD study from 2006 to 2016. The main analysis included a sample size of 214 patients with Typical ADPKD (Class 1). We evaluated the Mayo Clinic model performance calibration and discrimination in our external sample and assessed whether predictive performance could be improved through the addition of subsequent kidney volume measurements beyond the baseline assessment. Results: The calibration of both versions of the Mayo Clinic prediction model using continuous Height adjusted total kidney volume (HtTKV) and using risk subclasses was good, with R2 of 78% and 70%, respectively. Accuracy was also good with 91.5% and 88.7% of the predicted within 30% of the observed, respectively. Additional information regarding kidney volume did not substantially improve the model performance. Conclusion: The Mayo Clinic prediction models are generalizable to other clinical settings and provide an accurate tool based on available predictors to identify patients at high risk for rapid disease progression.

KW - ADPKD

KW - Disease progression

KW - Epidemiology

KW - Kidney volume

KW - Prediction model

KW - Validation study

UR - http://www.scopus.com/inward/record.url?scp=85024402717&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85024402717&partnerID=8YFLogxK

U2 - 10.1186/s12882-017-0654-y

DO - 10.1186/s12882-017-0654-y

M3 - Article

C2 - 28716055

AN - SCOPUS:85024402717

VL - 18

JO - BMC Nephrology

JF - BMC Nephrology

SN - 1471-2369

IS - 1

M1 - 241

ER -